Abstract
Upregulation of IGF2 occurs in both childhood and adult malignancies. Its overexpresssion is associated with resistance to chemotherapy and worse prognosis. IGF2 promoter usage is developmentally regulated; however, malignant tissues are characterized by re-activation of the fetal IGF2 promoters, especially P3. In this review, we describe the mechanisms of IGF2 signaling and regulation in normal and malignant tissues and their clinical implications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 371-377 |
| Number of pages | 7 |
| Journal | Cytokine and Growth Factor Reviews |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 1 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- Chemoresistance
- IGF2
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Immunology and Allergy
- Immunology
- General Biochemistry, Genetics and Molecular Biology
Fingerprint
Dive into the research topics of 'IGF2 signaling and regulation in cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS